XR Beta-TM 25 Tablet SR is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 25 mg in a sustained-release formulation. Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Metoprolol Succinate, a cardioselective beta-1 adrenergic receptor blocker, reduces heart rate, myocardial contractility, and cardiac output, contributing to effective blood pressure control and decreased myocardial oxygen demand. The sustained-release formulation ensures a gradual and consistent release of active ingredients, promoting improved patient compliance through once-daily dosing and stable plasma drug concentrations. XR Beta-TM 25 Tablet SR is indicated for the management of essential hypertension and is particularly beneficial in patients requiring combination therapy to achieve optimal blood pressure control. It may also be used in patients with concomitant cardiovascular conditions such as ischemic heart disease or heart failure where beta-blockade and renin-angiotensin system inhibition are warranted. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Regular monitoring of blood pressure, heart rate, and renal function is recommended during therapy.